+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biogen Inc. - logo

Founded in 1978 Biogen Inc is a global biotechnology company with its headquarters in Cambridge, Massachusetts. In 2003 Biogen merged with Idec Pharmaceuticals to create Biogen Idec and acquired Syntonix Pharmaceuticals in 2007. In 2015 the company returned to its original name Biogen Inc and acquired Convergence Pharmaceuticals. Biogen focuses on drug discovery for a range of conditions including neuropathic pain, hemophilia, organ failure, neuromuscular disorders and oncology. Their product portfolio includes Rituxan, Avonex, Tecfidera and Eloctate.

Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
From
From
From
Rituxan - Product Thumbnail Image

Rituxan

  • Report
  • January 2019
  • 82 Pages
  • Global
From
Global Uveitis Drugs Market 2022-2026 - Product Thumbnail Image

Global Uveitis Drugs Market 2022-2026

  • Report
  • June 2022
  • 120 Pages
  • Global
From
Axial Spondyloarthritis (axSpA) Global Market Report 2024 - Product Thumbnail Image

Axial Spondyloarthritis (axSpA) Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • February 2024
  • 93 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis - Global Strategic Business Report - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis - Global Strategic Business Report

  • Report
  • February 2024
  • 181 Pages
  • Global
From
From
Loading Indicator